AKBA Akebia Therapeutics, Inc. Stock Quote

AKBA [NASD]

Index	-	P/E	-	EPS (ttm)	-1.91	Insider Own	0.30%	Shs Outstand	173.78M	Perf Week	-6.55%
Market Cap	445.30M	Forward P/E	-	EPS next Y	-0.69	Insider Trans	-1.07%	Shs Float	172.71M	Perf Month	-17.89%
Income	-299.20M	PEG	-	EPS next Q	-0.09	Inst Own	59.60%	Short Float	5.98%	Perf Quarter	-15.74%
Sales	210.70M	P/S	2.11	EPS this Y	-17.20%	Inst Trans	-6.87%	Short Ratio	5.04	Perf Half Y	-22.82%
Book/sh	0.79	P/B	3.25	EPS next Y	50.90%	ROA	-48.10%	Target Price	6.54	Perf Year	-17.36%
Cash/sh	1.20	P/C	2.15	EPS next 5Y	-	ROE	-154.70%	52W Range	2.35 - 5.14	Perf YTD	-8.21%
Dividend	-	P/FCF	-	EPS past 5Y	-3.80%	ROI	-109.40%	52W High	-50.00%	Beta	1.56
Dividend %	-	Quick Ratio	1.60	Sales past 5Y	-	Gross Margin	35.70%	52W Low	9.36%	ATR	0.15
Employees	380	Current Ratio	1.70	Sales Q/Q	-18.70%	Oper. Margin	-	RSI (14)	39.16	Volatility	5.56% 5.48%
Optionable	Yes	Debt/Eq	0.71	EPS Q/Q	18.10%	Profit Margin	-	Rel Volume	1.60	Prev Close	2.71
Shortable	Yes	LT Debt/Eq	0.71	Earnings	Nov 04 BMO	Payout	-	Avg Volume	2.05M	Price	2.57
Recom	2.20	SMA20	-10.01%	SMA50	-10.28%	SMA200	-17.84%	Volume	3,287,899	Change	-5.17%

Mar-08-21

Initiated

Cantor Fitzgerald

Overweight

Jan-29-21

Downgrade

JP Morgan

Neutral → Underweight

Nov-14-19

Reiterated

Needham

Buy

$18 → $15

Aug-06-19

Reiterated

H.C. Wainwright

Buy

$19 → $17

Jul-11-19

Reiterated

H.C. Wainwright

Buy

$23 → $21

May-02-19

Initiated

JP Morgan

Overweight

$12

Mar-20-19

Initiated

Citigroup

Neutral

Sep-07-18

Resumed

Morgan Stanley

Equal-Weight

Aug-10-18

Reiterated

Needham

Buy

$20 → $18

Jun-06-18

Reiterated

H.C. Wainwright

Buy

$24 → $22

Dec-19-17

Initiated

Piper Jaffray

Overweight

$26

Dec-07-17

Initiated

BTIG Research

Buy

$30

Sep-15-17

Initiated

RBC Capital Mkts

Sector Perform

$17

Jul-10-17

Reiterated

H.C. Wainwright

Buy

$25 → $24

Apr-27-17

Reiterated

Needham

Buy

$14 → $18

Apr-27-17

Reiterated

H.C. Wainwright

Buy

$18 → $21

Dec-27-16

Reiterated

H.C. Wainwright

Buy

$17 → $18

Dec-20-16

Reiterated

JMP Securities

Mkt Outperform

$16 → $19

Nov-15-16

Initiated

Aegis Capital

Buy

Sep-29-16

Initiated

Brean Capital

Buy

Dec-01-21 04:25PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire -5.17%
Nov-24-21 08:30AM	Akebia Therapeutics Announces Participation in Upcoming Investor Conferences PR Newswire
Nov-15-21 08:30AM	Akebia Therapeutics to Present at Jefferies London Healthcare Conference PR Newswire
Nov-14-21 08:53AM	10 Best Biotech Stocks Under $5 Insider Monkey
Nov-09-21 11:31PM	Akebia Therapeutics, inc (AKBA) Q3 2021 Earnings Call Transcript Motley Fool
Nov-04-21 09:25AM	Akebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue Estimates Zacks -8.98%
08:05AM	Akebia Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Company Milestones PR Newswire
Nov-01-21 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire +9.06%
08:00AM	Akebia Therapeutics Appoints Ron Frieson, Healthcare Operations Leader, to Board of Directors PR Newswire
Oct-29-21 08:00AM	Akebia Announces Otsuka's Submission of Initial Marketing Authorization Application to the European Medicines Agency for Vadadustat for the Treatment of Patients with Anemia due to Chronic Kidney Disease PR Newswire
Oct-28-21 03:06PM	Akebia Therapeutics (AKBA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks +5.58%
Oct-26-21 08:00AM	Akebia Therapeutics to Report Third Quarter 2021 Financial Results and Highlight Recent Company Milestones PR Newswire
Oct-25-21 04:39PM	Statement from Akebia Therapeutics Regarding Litigation Against Centers for Medicare & Medicaid Services and the U.S. Department of Health and Human Services PR Newswire
Oct-21-21 06:34AM	Here's What Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Shareholder Ownership Structure Looks Like Simply Wall St.
Oct-18-21 08:00AM	Akebia Announces Vadadustat Efficacy and Safety Data to be Presented at American Society of Nephrology Kidney Week 2021 PR Newswire
Oct-01-21 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Sep-06-21 06:23AM	Health Check: How Prudently Does Akebia Therapeutics (NASDAQ:AKBA) Use Debt? Simply Wall St.
Sep-01-21 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
08:00AM	Akebia Therapeutics Announces September 2021 Investor Conference Schedule PR Newswire
Aug-05-21 04:31PM	Akebia Therapeutics, inc (AKBA) Q2 2021 Earnings Call Transcript Motley Fool +15.73%
04:00PM	Why Akebia Therapeutics Stock Is Soaring Today Motley Fool
09:15AM	Akebia Therapeutics (AKBA) Reports Q2 Loss, Misses Revenue Estimates Zacks
07:58AM	Akebia Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Company Milestones PR Newswire
Aug-03-21 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Jul-29-21 03:05PM	Akebia Therapeutics (AKBA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Jul-27-21 06:15PM	INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Akebia Therapeutics, Inc. and Encourages Investors who Formerly Held Shares of Keryx Biopharmaceuticals (KERX) to Contact the Firm Business Wire
Jul-26-21 01:47PM	SHAREHOLDER ALERT: Robbins LLP Announces that Akebia Therapeutics, Inc. (AKBA) is Being Sued for Misleading Keryx Biopharmaceuticals, Inc. (KERX) Shareholders Ahead of Merger Business Wire
08:00AM	Akebia Therapeutics to Report Second Quarter 2021 Financial Results and Discuss Recent Business Highlights PR Newswire
Jul-01-21 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Jun-18-21 12:58PM	Investigation Alert: The Schall Law Firm Announces it is Investigating Claims Against Akebia Therapeutics, Inc. and Encourages Investors Who Formerly Held Shares of Keryx Biopharmaceuticals (KERX) to Contact the Firm Newsfile
Jun-08-21 01:20AM	Reflecting on Akebia Therapeutics' (NASDAQ:AKBA) Share Price Returns Over The Last Year Simply Wall St.
Jun-04-21 10:27AM	Cyclerion Out-Licenses Praliciguat to Akebia, Announces $18M Capital Raise Benzinga
Jun-03-21 08:00AM	Akebia Therapeutics Announces Presentations at ERA-EDTA Virtual Congress 2021 PR Newswire
Jun-02-21 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Jun-01-21 06:00AM	Akebia and Otsuka Announce FDA Acceptance for Filing of New Drug Application for Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis and Not on Dialysis PR Newswire
May-25-21 08:10AM	Implied Volatility Surging for Akebia Therapeutics (AKBA) Stock Options Zacks
May-12-21 09:11AM	New Strong Sell Stocks for May 12th Zacks
May-10-21 09:20AM	Akebia Therapeutics (AKBA) Reports Q1 Loss, Tops Revenue Estimates Zacks -7.05%
08:00AM	Akebia Reports First Quarter 2021 Financial Results and Highlights Recent Company Milestones PR Newswire
07:15AM	Akebia Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
May-04-21 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire -6.92%
Apr-28-21 05:19PM	New England Journal of Medicine Publishes Results of Global Phase 3 Clinical Program of Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease PR Newswire
08:00AM	Akebia Therapeutics to Report First Quarter 2021 Financial Results and Discuss Recent Business Highlights PR Newswire
Apr-26-21 08:15AM	SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Akebia Therapeutics, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors PR Newswire
Apr-24-21 03:16AM	What Type Of Shareholders Own The Most Number of Akebia Therapeutics, Inc. (NASDAQ:AKBA) Shares? Simply Wall St.
Apr-12-21 08:00AM	Akebia Therapeutics to Present at 20th Annual Needham Virtual Healthcare Conference PR Newswire
Apr-02-21 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Mar-31-21 09:24AM	Akebia (AKBA) Files NDA for Vadadustat for Anemia Due to CKD Zacks +9.37%
Mar-30-21 06:00AM	Akebia Submits New Drug Application (NDA) to the FDA for Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis and Not on Dialysis PR Newswire
Mar-25-21 08:00AM	Akebia Therapeutics Announces Poster Presentations and Educational Symposium at National Kidney Foundation 2021 Virtual Spring Clinical Meetings PR Newswire +5.88%
Mar-24-21 08:00AM	Akebia Therapeutics Announces Approval for Additional Indication of Riona® (ferric citrate hydrate) for the Treatment of Iron Deficiency Anemia in Adult Patients in Japan PR Newswire
Mar-11-21 08:00AM	Akebia Therapeutics Celebrates World Kidney Day and National Kidney Month PR Newswire +5.68%
Mar-09-21 11:32PM	Is Akebia Therapeutics (NASDAQ:AKBA) Using Debt Sensibly? Simply Wall St. +8.11%
Mar-02-21 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
10:41AM	Looking Into Akebia Therapeutics's Return On Capital Employed Benzinga
Feb-25-21 12:47PM	Why Akebia Therapeutics Stock Is Plunging Today Motley Fool -18.93%
08:00AM	Akebia Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides Business Updates PR Newswire
Feb-18-21 08:00AM	Akebia Therapeutics Appoints LeAnne M. Zumwalt, Dialysis Industry Leader, to Board of Directors PR Newswire -6.41%
Feb-08-21 08:00AM	Akebia Therapeutics to Report Fourth Quarter and Full-Year 2020 Financial Results and Discuss Recent Business Highlights PR Newswire +12.20%
Feb-02-21 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Feb-01-21 10:05PM	10 Underperforming Stocks Targeted By Short Sellers Insider Monkey +5.09%
Jan-29-21 10:32AM	Return On Capital Employed Overview: Akebia Therapeutics Benzinga -5.40%
Jan-06-21 08:00AM	Akebia Therapeutics to Present at H.C. Wainwright Bioconnect 2021 Conference PR Newswire
Jan-05-21 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Jan-04-21 08:00AM	Akebia Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-16-20 02:16PM	Is AKBA A Good Stock To Buy Now? Insider Monkey
08:43AM	Implied Volatility Surging for Akebia Therapeutics (AKBA) Stock Options Zacks
Dec-09-20 08:00AM	AkebiaShares Program: Current Approaches for Managing Hyperphosphatemia and Caring for Patients via Telehealth PR Newswire -8.01%
Dec-02-20 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Nov-24-20 08:00AM	Akebia Therapeutics to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference PR Newswire
Nov-18-20 09:37AM	Akebia Therapeutics Ranked 10th Fastest-Growing Company in North America on Deloitte's 2020 Technology Fast 500 PR Newswire
Nov-16-20 08:30AM	Akebia Announces Manuscript Highlighting Global Phase 3 INNO2VATE Program Rationale, Study Design and Baseline Characteristics Published in Peer-Reviewed Medical Journal PR Newswire
Nov-12-20 08:40AM	Is the Options Market Predicting a Spike in Akebia (AKBA) Stock? Zacks
Nov-10-20 05:01AM	Akebia Therapeutics, Inc. (NASDAQ:AKBA) Analysts Are Reducing Their Forecasts For Next Year Simply Wall St. +5.71%
Nov-07-20 07:18AM	Akebia Therapeutics, Inc. (NASDAQ:AKBA) Just Reported And Analysts Have Been Cutting Their Estimates Simply Wall St.
Nov-05-20 11:31PM	Akebia Therapeutics Inc (AKBA) Q3 2020 Earnings Call Transcript Motley Fool
09:35AM	Akebia Therapeutics (AKBA) Reports Q3 Loss, Lags Revenue Estimates Zacks
08:03AM	Akebia Reports Third Quarter 2020 Financial Results and Recent Business Updates PR Newswire
Nov-03-20 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Oct-29-20 12:35PM	Akebia Therapeutics (AKBA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Oct-26-20 08:00AM	Akebia Therapeutics to Report Third Quarter 2020 Financial Results and Discuss Recent Business Highlights PR Newswire -10.69%
Oct-23-20 11:15AM	Akebia Presents Results from its PRO2TECT Global Phase 3 Program of Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients Not on Dialysis During Late-Breaking Session at American Society of Nephrology Kidney Week 2020 Reimagined PR Newswire
07:26AM	The Daily Biotech Pulse: Gilead Gets Full Approval For Remdesivir, Akebia's Positive Readout, Foghorn IPO Benzinga
Oct-22-20 05:05PM	Akebia Presents Results from its INNO2VATE Global Phase 3 Program; Demonstrated Efficacy and Cardiovascular Safety of Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis PR Newswire
Oct-13-20 08:40AM	Akebia Therapeutics (AKBA) Looks Good: Stock Adds 6.7% in Session Zacks +6.93%
Oct-09-20 04:49PM	Akebia to Present Global Phase 3 Vadadustat Data at American Society of Nephrology Kidney Week 2020 Reimagined PR Newswire +5.42%
Oct-08-20 08:54AM	Do Options Traders Know Something About Akebia (AKBA) Stock We Don't? Zacks
Oct-02-20 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Sep-29-20 05:27PM	Hedge Funds Have Never Been This Bullish On Akebia Therapeutics Inc (AKBA) Insider Monkey
Sep-26-20 08:50AM	Is Akebia Therapeutics (NASDAQ:AKBA) Using Debt Sensibly? Simply Wall St.
Sep-08-20 08:00AM	Akebia Therapeutics Announces September 2020 Investor Conference Schedule PR Newswire
Sep-04-20 12:55PM	Akebia Falls as Vadadustat Fails to Meet Safety Endpoint Zacks
Sep-03-20 11:55AM	Why Akebia Therapeutics Stock Is Crashing Today Motley Fool -73.50%
09:53AM	ROCE Insights For Akebia Therapeutics Benzinga
07:00AM	Akebia Therapeutics Announces Top-Line Results from its PRO2TECT Global Phase 3 Program of Vadadustat for Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients Not on Dialysis PR Newswire
Sep-02-20 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Aug-26-20 08:41AM	Implied Volatility Surging for Akebia (AKBA) Stock Options Zacks
08:00AM	Akebia Therapeutics Announces First Commercial Launch of VAFSEO (vadadustat tablets), a New Oral Treatment for Anemia Due to Chronic Kidney Disease, in Japan PR Newswire
Aug-12-20 07:08AM	If You Had Bought Akebia Therapeutics (NASDAQ:AKBA) Stock A Year Ago, You Could Pocket A 132% Gain Today Simply Wall St.
07:07AM	Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Path To Profitability Simply Wall St.

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Burke Steven Keith	SVP, Chief Medical Officer	Aug 31	Sale	2.83	1,042	2,949	171,219	Sep 02 04:07 PM
GILMAN STEVEN C	Director	Jun 07	Sale	3.32	4,567	15,163	47,997	Jun 09 04:26 PM
Butler John P.	CEO and President	Mar 01	Sale	3.40	49,990	169,771	1,116,742	Mar 02 04:10 PM
Dahan Michel	SVP, Chief Operating Officer	Mar 01	Sale	3.40	14,547	49,403	255,113	Mar 02 04:08 PM
Hadas Nicole R.	SVP, Chief Legal Officer	Mar 01	Sale	3.40	14,285	48,513	263,171	Mar 02 04:08 PM
Faulkingham Dell	CCO	Mar 01	Sale	3.40	6,749	22,920	128,825	Mar 02 04:08 PM
Burke Steven Keith	SVP, Chief Medical Officer	Mar 01	Sale	3.40	7,558	25,668	161,442	Mar 02 04:06 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience